The aim of this double-blind single center study (the COPE study)
longed ICS treatment is not yet clear. Only two studies have
related quality of life investigated the effect of withdrawal of ICS: one observational, nonrandomized, study (19) as part of the run-in phase Chronic obstructive pulmonary disease (COPD) constitutes a of the ISOLDE study (13) and a small, underpowered crossmajor public health burden worldwide (1) . The World Health over study with a short follow-up and no wash-out period Organization (2) estimates COPD to be the world's fifth most (20) . As most of the newly diagnosed patients with COPD common disease and fourth leading cause of death. Both receive initial trial treatment for several months, and many prevalence and mortality are expected to increase in the of them will show the initial improvement in FEV 1 , they will coming decades (3, 4) . be prescribed ICS for life. Therefore, there is an urgent need Smoking cessation (5) and bronchodilator therapy (5, 6) for large randomized controlled studies on discontinuation are the mainstay of the management of COPD. Born from of ICS treatment. the idea that both asthma and COPD result from chronic
We investigated the effect of discontinuing maintenance inflammation and that inhaled corticosteroids (ICS) are retherapy with high doses (1,000 g/day) of inhaled fluticasone markably effective in controlling inflammation in asthma, there propionate (FP) in a randomized, double-blind, placebo conis an intense discussion whether or not ICS are beneficial in trolled study (COPE study) on time to first exacerbation and COPD (7, 8) . Inevitably, clinicians have prescribed ICS in rapid recurrence of well-defined exacerbations in patients with moderate to severe COPD.
METHODS
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Patients
The COPE study was sponsored by the Netherlands Asthma Foundation, Amicon Health Insurance Co., Boehringer Ingelheim, and GlaxoSmithKline BV.
All patients were recruited from one outpatient pulmonary clinic, from May 1999 till March 2000. To be eligible for the study the patients had
Part of the results of this study were presented at the annual meeting of the to meet the following criteria: (1 ) dicted value or less (22); (9 ) thin layer chromatography greater than the thin layer chromatography predicted minus 1.64 SD; (10) no maintedomization and after 3 and 6 months follow-up. Well-trained lung function technicians performed spirometry on water sealed spirometers nance treatment of oral steroids or antibiotics; (11) no medical condition with low survival or serious psychiatric morbidity (e.g., cardiac insuffiaccording to standardized guidelines (25) and FEV 1 and IVC were measured until three reproducible recordings (less than 5% difference) ciency, alcoholism); (12) absence of any other active lung disease (e.g., sarcoidosis); and (13) use of medication such as nasal corticosteroids, were obtained. Highest values were used for analyses. Exercise tolerance was measured at randomization and after 6 months follow-up by theophyllines, chronic use of acetylcysteine, and all other bronchodilators was allowed.
the standardized 6-minute walking test. Oxygen saturation, heart rate, and the Borg scale of breathlessness by means of a 11-point scale were The hospital's medical ethical committee approved this study. All patients provided written informed consent.
recorded pretest and after every minute (26) . The performance of the test was standardized: patients performed a practice walk, were instructed Trial Design pretest, and no encouragement was used during the test (27) . A change of 54 m in walking distance is considered clinically important (28). This study was a randomized, double-blind, parallel-group single center Use of health care facilities was registered during the study: hospitalstudy that comprised 4 months run-in, 6 months active treatment or izations, emergency room visits, scheduled and emergency outpatient placebo, with follow-up visits at 3 and 6 months. In the run-in phase all visits, and exacerbations treated by the patient's general practitioner. patients were prescribed FP via Diskus/Accuhaler 500 g twice daily and
Pharmacists reported all drugs used during the study period. ipratropiumbromide 40 g four times daily to optimize lung function.
Patients were asked to complete a 2-week diary before each followAll patients were prescribed short-acting ␤2-agonists (salbutamol) as up visit and during periods of increased respiratory symptoms. In the rescue medication. Patients using rescue medication more than twice daily diary, data on breathlessness, cough, sputum volume, sputum color, were offered a long-acting ␤2-agonist. All patients received inhalation and use of rescue ␤2-agonists was collected. Every week patients graded instruction in small group sessions at the start of the study. Current their health status from 1 to 10. At each visit patients were questioned smokers were offered an individual smoking cessation program (23).
about possible adverse events. After 4 months, eligible patients were randomly assigned to continue 500 g of FP twice daily or to receive placebo administered via the Statistical Analyses Diskus inhalation device for 6 months. Randomization was performed in blocks of six by computer-generated allocation. Follow-up visits were
We calculated that 192 patients (96 per treatment group) were required scheduled 3 and 6 months post randomization. Spirometry at regular to detect a hazard ratio of a first exacerbation of 1.50 (FP compared follow-up visits was measured under postbronchodilation medication with placebo) with 80% power and a two-sided 0.05 ␣-level test (29) . and only when the patient was in a stable condition. If the patient was Baseline characteristics are reported as means Ϯ SD or as percentusing a short course of oral steroids or antibiotics or was experiencing an ages within groups. Analyses were performed according to the intenexacerbation at the time of the follow-up visit, this visit was postponed tion-to-treat principle. The effect of discontinuing FP on the subsequent 4 weeks. exacerbation risk (the primary outcome) was assessed using Cox proIf patients experienced any worsening of their respiratory symptoms portional hazard analyses. Between-group differences in the proportion they were instructed to contact the COPE study personnel by telephone.
of patients with rapid recurrences of exacerbations were assessed by They were subsequently invited to attend the hospital within 12 hours means of chi-square tests. for spirometry measurements and consultation by one of the study Between-group differences in continuous variables (Quality-of-Lifephysicians who subsequently decided either to continue the trial or to scores, lung function parameters) were assessed by analyses of repeated prescribe 500 g of FP twice daily unblinded. The latter was allowed measurements using Proc Mixed (mixed models approach) from SAS according to the benefit of the doubt principle in case patients experi-(30). Linear regression analysis was used to assess between-group differenced rapid recurrent exacerbations. This was defined as either twice ences for the distance walked in 6 minutes. an objective increase in respiratory symptoms within a 3-month period, Within-patient comparisons were done by the paired t test (normal defined as more than 20% or 300 ml decrease in FEV 1 , compared distribution) or the Wilcoxon Signed Rank Test (non-normal distribuwith stable lung function at randomization, or three times a subjective tion). We adjusted the analyses for potential confounding variables if increase of respiratory symptoms in a 3-month period as experienced these variables were not equally distributed at randomization. by the patient regardless of the criteria mentioned previously.
We performed subgroup analyses for the patients with a FEV 1 value less than 50% predicted according to the GOLD recommendations for Outcome Measurements ICS prescription (1) . Except for the repeated measurements analyses, all statistical analyPrimary outcome measures were first and second exacerbation and ses were performed using SPSS version 10 (31). the occurrence of rapid recurrent exacerbations, as well as HRQL. Exacerbations were defined as worsening of respiratory symptoms that required treatment with a short course of oral corticosteroids or antibi-
RESULTS
otics as judged by the study physician. A short course of oral corticosteBaseline Characteristics roids was defined as 30 mg prednisolon for a period of 10 days. The first choice of antibiotics was amoxicillin/clavulanic acid 625 mg four Of the 509 eligible patients, a total of 269 were enrolled times daily for a period of 10 days. The second choice was doxycycline ( Figure 1 ). The mean age of the participants was 64.0 Ϯ 7.2 100 mg daily for a period of 10 days. Exacerbations were followed years. Table 1 shows the baseline characteristics of the study actively as described in Trial Design.
population stratified by treatment group. Except for smoking Patients with rapid recurrence of exacerbations were those who had the two treatment groups were similar with respect to the known to be prescribed FP unblinded due to safety reasons as mentioned prognostic variables. Eighty-three percent (203/244) of the papreviously. HRQL was measured immediately before randomization tients had used ICS at least 6 months before entering the study. the FP group (from cancer) and the other in the placebo group for smoking status in the placebo group compared with the FP group was 2.4 (95% CI 1.5-3.9). from a cerebrovascular accident (Figure 1 ).
In the placebo group, 26 patients (21.5%) experienced rapid slightly higher exacerbation rate pretrial, a worse health status, Figure 3 . Adjusted for baseline differences, smoking status, and time effects, a small but statistically significant difference in mean and walked less in 6 minutes. The lung function of this subgroup did not differ from the overall study population. Analysis of the Euroqol-5D visual analogue scale-score of 3.1 points (95% CI subgroup of patients with a FEV 1 value less than 50% predicted 0.8-5.3) in favor of the FP group was observed. (low FEV 1 group) suggests that the difference in time to first
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exacerbation between groups is driven by this subset. The hazard ratio was 2.1 (95% CI 1.1-3.6) and 1.2 (95% CI 0.8-2.0) in the During the 4-month run-in period, FEV 1 did not change. Adlow-and high-FEV 1 group, respectively. justed for baseline values, smoking status, and time effects, an almost statistically significant difference of 38 ml in postbron-
Health-related Quality of Life
chodilation FEV 1 was observed in favor of the FP group. Mean Adjusted for baseline scores, smoking status, and time effects, distance walked in 6 minutes and mean Borg score of breatha statistically significant difference was observed between both lessness remained unchanged (Table 2) . groups in the total score (ϩ2.48, 95% CI 0.37-4.58), in the activity Safety domain (ϩ4.64, 95% CI: 1.60-7.68) and the symptom domain (ϩ4.58, 95% CI: 1.05-8.10) over 6 months. No difference was
In concordance with the primary outcome results, the frequency seen in the impact domain. The results are summarized in of serious adverse respiratory events (mainly hospital admissions for exacerbations of COPD) was higher in the placebo group (Table 3) . There was no indication that FP caused serious or nonserious adverse events.
DISCUSSION
This randomized placebo-controlled study demonstrated that discontinuation of FP (1,000 g/day) after 4 months of maintenance therapy induced a more rapid onset and higher recurrencerisk of exacerbations in patients with moderate to severe COPD. The study was motivated by the observation in two earlier 
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Definition of abbreviations: CI ϭ confidence interval; FP ϭ fluticasone propionate. * Analysis of treatment differences were adjusted for smoking status and baseline values. † Based on repeated measurements analyses with Proc Mixed. ‡ Numbers are smaller than randomized population for 6-minute walk distance and Borg score because of practical problems not all patients performed a 6-minute walk. Patients were randomly assigned to a do a 6-minute walk.
§ Based on linear regression analysis.
studies (13, 17) showing that ICS produces a small, initial immeasured (13, 14) . By contrast, the COPE study was designed provement in FEV 1 without additional reduction in lung function to investigate the effect of discontinuing ICS on first and second loss in subsequent years. Before enrollment in the present study, exacerbation and occurrence of rapid recurrence of well-defined 85% of patients with COPD were receiving ICS, which may exacerbations. The exacerbation data of our study can be considexplain the lack of the improvement in FEV 1 during the run-in ered very reliable because all patients were instructed to call period.
and visit the COPE center as soon as they experienced any The increased risk of exacerbations after withdrawal of ICS serious worsening of their respiratory condition, to clinically is in accordance with the limited evidence available (19, 20) . In verify the suspicion of an exacerbation. In all these instances the run-in phase of the ISOLDE study (19), ICS were withheld lung function tests were performed within 12 hours. In addition, from patients already using these medications. In the first 7 all diaries, week reports, hospital records (hospitalizations and weeks post withdrawal, 38% of patients previously treated with emergency department visits), and records from the patient's ICS experienced an exacerbation compared with 6% of those general practitioner and pharmacists were searched for addiwho had not received ICS previously. Although the patients in tional information on exacerbations. the ISOLDE study were more severe, the higher frequency of Assessment of the HRQL, which is an important outcome exacerbations seen in the COPE study after withdrawal of ICS in COPD studies (10) , provided us with a comprehensive picture might be explained by a prospective and complete registration of the overall impact of FP treatment withdrawal in COPD (32). of exacerbations. In agreement with the ISOLDE study, the This study showed a significant deterioration in the total score, majority of exacerbations in our study occurred in the first 7 symptoms, and activity domains of the St. George's Respiratory weeks. The study by O'Brien and colleagues (20) demonstrated Questionnaire in the placebo group. This suggests that discontinthat withdrawal of ICS in elderly patients with COPD led to uation of FP affects distress, due to respiratory symptoms, and deterioration in ventilatory function and increased exercise-indisturbance of physical activity but does not affect the impact duced dyspnea and showed a trend toward an increased freon daily living. These findings are in line with the study by quency of exacerbations. However, results of this small crossover Spencer and colleagues (33). Their results suggest that FP has study should be viewed with caution as only 15 of the 24 patients greatest influence on deterioration in physical aspects of health completed the study, and follow-up was only 12 weeks. Morerather than psychosocial functions. Another study assessing the over, lung function varied considerably (range of FEV 1 between effect of exacerbations on HRQL in COPD, however, showed a 0.73 and 2.42 L), and the only three patients with exacerbations worse St. George's Respiratory Questionnaire total and domain were withdrawn. Also our own results regarding the larger descores in patients with frequent exacerbations (34). Based on cline in FEV 1 in the placebo group should be viewed with caution.
this study, one expects worse health status in our patients in the The difference of 38 ml seems relevant but is based only on placebo group because of their higher rate of exacerbations. three measurements in a period of 6 months.
However, it should be noted that the patients with frequent It should further be stressed that in most studies on effects exacerbations in the COPE study received open FP treatment of ICS in COPD (including the two studies dealing with effects for safety reasons most times already before the first follow-up of ICS withdrawal), exacerbations were only considered a secvisit, and this may have lead to dilution of the effect on HRQL. ondary outcome and hence were poorly defined, described, or
We did not find relevant differences in the Eurol-5D visual analogue scale score within and between treatment groups, a finding concordant with the view that a global assessment of patients' health underestimates the impact of airways disease (32) .
Fluticasone Proprionate Placebo
Further research is needed to analyze the clinical intangible
factors of sensitivity to ICS as it is still not well understood why
No. of serious adverse events patients with COPD would benefit from ICS. In addition it
Total (no. of points) 14 (12) 24 (13) should be stressed that patients treated at a chest clinic in the A hypothetical explanation for ICS sensitivity could be the At 3 months follow-up 4 7 inclusion of patients with COPD who also have asthma features.
At end of study 2 1 Although patients with a history of asthma or reversible bron-Multicentre randomised placebo-controlled trial of inhaled fluticasone chial obstruction were excluded, some patients might have hidpropionate in patients with chronic obstructive pulmonary disease:
den asthma-like characteristics and thus were probably prone 
